India, May 12 -- Bristol Myers Squibb (BMY) and Hengrui Pharma (01276.HK) announced a strategic collaboration and license agreements to advance a portfolio of 13 early-stage programs in oncology, hematology and immunology. The partnership is designed to accelerate discovery and development of innovative medicines for the benefit of patients worldwide.
The agreements include four oncology/hematology assets from Hengrui, four immunology assets from BMS, and five jointly discovered programs leveraging Hengrui's discovery engine and platform technologies. Under the terms, BMS obtains exclusive worldwide rights to Hengrui originated assets outside China, Hong Kong, and Macau, while Hengrui secures exclusive rights to BMS originated assets withi...